Leadership Planning and Evaluation

The University of Michigan (U-M) Rogel Cancer Center (Rogel) has an effective and long-standing process for leadership, planning and evaluation that engages Senior Leaders, Program Leaders, internal and external leaders, Shared Resource (SR) Directors, Rogel members and staff. Rogel’s Senior Leadership is comprised of nationally recognized, engaged experts who are strongly committed to the mission and vision of the Rogel Cancer Center. Eric Fearon, MD, PhD, is Director of the Rogel Cancer Center and Associate Dean for Cancer Programs in the U-M Medical School. Fearon is supported by highly engaged, expert senior leadership and advisory committees. The Senior Leadership Council (SLC), which meets weekly, is comprised of the Director, Deputy Director, and 11 Associate Directors. The SLC regularly engages with the Rogel Executive Committee (EC), comprised of SLC and Research Program Leaders, Assistant Directors in COE and TrEC, SPORE leadership, the Emerging Leaders Council Chair and Vice Chairs, senior advisors and communications. The EC meets monthly and enables the SLC to discuss and jointly set priorities and future direction with PLs, as well as allows the PLs and others to give feedback to the SLC on research progress and new developments. The Rogel External Advisory Board (EAB) is a vital part of Rogel’s planning and evaluation process. The EAB, comprised of national leaders with expertise in areas that align with Rogel’s Research Programs, SRs and components, meets at least yearly and provides objective guidance and direction on Rogel’s strategic planning and initiatives. Rogel also engages several internal and external advisory committees to provide objective oversight of SRs, TrEC, COE, clinical research, and clinical services. Planning and Evaluation is essential to the cancer center’s research mission and a regular part of the senior leadership’s activities. The 2022-2027 Rogel Strategic Plan – Discovery to Cures to Communities – is supported by the following pillars: research; community outreach; education and training; infrastructure and clinical research; and patient care. The SLC, with support from the EC, will lead the implementation and execution of the new strategic plan, as well as monitor progress against goals, inform resource allocation, and make course corrections as necessary. These processes and committees enable the SLC to promote: i) collaborative, transdisciplinary research across the cancer research continuum to advance Rogel’s scientific innovations; ii) programs in training, education and career development to empower the next generation of cancer researchers and providers; and iii) community engagement, research and educational initiatives to address the cancer burden across the catchment area and beyond.